Prognostic significance of SOX2 for chemotherapeutic patients with oral squamous cell carcinoma  

作　　者：Xuefeng Zhang Hao Xu Tong Zhou Xiaodong Feng Qianming Chen 

机构地区：[1]State Key Laboratory of Oral Diseases,National Center of Stomatology,National Clinical Research Center for Oral Diseases,West China Hospital of Stomatology,Sichuan University,Chengdu,610041,China

出　　处：《Journal of Pharmaceutical Analysis》2024年第4期619-621,共3页药物分析学报（英文版）

基　　金：supported by the National Natural Science Foundation of China(Grant No.:82002877);the Scientific Research Foundation for Recruited Talents,West China Hospital of Stomatology,Sichuan University,China(Grant No.:QDJF2019-3);the Fundamental Research Funds for the Central Universities,China(Grant No.:YJ201987);Sichuan Science and Technology Program,China(Grant No.:2021ZYD0090).

摘　　要：Oral squamous cell carcinoma(OSCC)is the most common oral cancers worldwide,accounting for over 90%of all oral malignancies[1].Despite encouraging improvements in therapeutic approaches,including surgical resection,chemotherapy,and radiotherapy,the five-year overall survival rate of OSCC has not been improved significantly over the past decades,mainly due to the high ratio of tumor recurrence and metastasis.

关 键 词：SOX2 THERAPEUTIC SQUAMOUS 

分 类 号：R735.1[医药卫生—肿瘤]